EGFR and non-small cell lung carcinoma: Later, in 2018, based on the IMpower150 trial (NCT02366143), atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin was approved for the first‐line treatment of advanced nonsquamous NSCLC without EGFR or ALK mutation.345